Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Equities research analysts at HC Wainwright cut their Q4 2024 EPS estimates for Entera Bio in a note issued to investors on Monday, May 13th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.07) per share for the quarter, down from their prior estimate of ($0.06). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Entera Bio's current full-year earnings is ($0.25) per share.
Entera Bio (NASDAQ:ENTX - Get Free Report) last released its quarterly earnings data on Friday, March 8th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01.
Entera Bio Stock Performance
Shares of NASDAQ:ENTX traded up $0.11 during trading on Wednesday, reaching $2.62. 199,610 shares of the stock were exchanged, compared to its average volume of 206,234. Entera Bio has a 12-month low of $0.52 and a 12-month high of $3.35. The firm's 50-day moving average price is $1.95 and its 200 day moving average price is $1.22. The firm has a market cap of $67.40 million, a price-to-earnings ratio of -9.32 and a beta of 1.63.
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Read More
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
